Coherus BioSciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.32 | -$0.21 | -$0.25 |
| Q2 2024 | 1 | -$0.31 | -$0.21 | -$0.25 |
| Q3 2024 | 1 | -$0.20 | -$0.14 | -$0.16 |
| Q4 2024 | 2 | -$0.38 | -$0.25 | -$0.30 |
| Q1 2025 | 2 | -$0.06 | -$0.04 | -$0.05 |
| Q2 2025 | 1 | -$0.06 | -$0.04 | -$0.05 |
| Q3 2025 | 1 | -$0.06 | -$0.04 | -$0.05 |
| Q4 2025 | 1 | -$0.06 | -$0.04 | -$0.05 |
Coherus BioSciences, Inc. Earnings Date And Information
Coherus BioSciences, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.01 earnings per share for the quarter, topping analysts' consensus estimates of $-0.1 by $0.09. The company had revenue of 70.77 M for the quarter and had revenue of 257.24 M for the year. Coherus BioSciences, Inc. has generated $-3 earnings per share over the last year ($-2.53 diluted earnings per share) and currently has a price-to-earnings ratio of -279.06. Coherus BioSciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
Coherus BioSciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.10 | -$0.09 | 0.01 | $58.98 M | $70.77 M |
| 08/08/2024 | Q2 2024 | -$0.21 | -$0.11 | 0.1 | $62.06 M | $64.98 M |
| 05/09/2024 | Q1 2024 | -$0.05 | $0.91 | 0.96 | $77.06 M | |
| 03/15/2024 | Q4 2023 | -$0.71 | $91.52 M | |||
| 11/06/2023 | Q3 2023 | -$0.21 | -$0.41 | -0.2 | $81.78 M | $74.57 M |
| 08/02/2023 | Q2 2023 | -$0.52 | -$0.49 | 0.03 | $50.47 M | $58.72 M |
| 05/08/2023 | Q1 2023 | -$0.61 | -$0.94 | -0.33 | $32.44 M | |
| 03/06/2023 | Q4 2022 | -$0.64 | -$0.85 | -0.21 | $45.35 M | |
| 11/08/2022 | Q3 2022 | -$0.53 | -$1.19 | -0.66 | $56.69 M | $45.42 M |
| 08/04/2022 | Q2 2022 | -$0.96 | -$0.73 | 0.23 | $62.04 M | $60.15 M |
| 05/05/2022 | Q1 2022 | -$0.80 | -$1.44 | -0.64 | $60.12 M | |
| 02/23/2022 | Q4 2021 | -$0.60 | $73.37 M | |||
| 11/08/2021 | Q3 2021 | -$0.40 | -$0.49 | -0.09 | $90.69 M | $82.50 M |
| 08/05/2021 | Q2 2021 | -$0.25 | -$0.40 | -0.15 | $87.04 M | $87.64 M |
| 05/06/2021 | Q1 2021 | $0.09 | -$2.37 | -2.46 | $83.03 M | |
| 02/25/2021 | Q4 2020 | $0.13 | $110.42 M | |||
| 11/05/2020 | Q3 2020 | $0.41 | $0.39 | -0.02 | $124.01 M | $113.55 M |
| 08/06/2020 | Q2 2020 | $0.33 | $0.83 | 0.5 | $102.52 M | $135.67 M |
| 05/07/2020 | Q1 2020 | $0.56 | $0.50 | -0.06 | $116.18 M | |
| 02/27/2020 | Q4 2019 | $0.72 | $0.56 | -0.16 | $123.86 M |
Coherus BioSciences, Inc. Earnings: Frequently Asked Questions
-
When is Coherus BioSciences, Inc.'s earnings date?
Coherus BioSciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
-
Did Coherus BioSciences, Inc. beat their earnings estimates last quarter?
In the previous quarter, Coherus BioSciences, Inc. (:CHRS) reported $-0.01 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.1 by $0.09.
-
How can I listen to Coherus BioSciences, Inc.'s earnings conference call?
The conference call for Coherus BioSciences, Inc.'s latest earnings report can be listened to online.
-
How can I read Coherus BioSciences, Inc.'s conference call transcript?
The conference call transcript for Coherus BioSciences, Inc.'s latest earnings report can be read online.
-
How much revenue does Coherus BioSciences, Inc. generate each year?
Coherus BioSciences, Inc. (:CHRS) has a recorded annual revenue of $257.24 M.
-
How much profit does Coherus BioSciences, Inc. generate each year?
Coherus BioSciences, Inc. (:CHRS) has a recorded net income of $257.24 M. Coherus BioSciences, Inc. has generated $-2.53 earnings per share over the last four quarters.
-
What is Coherus BioSciences, Inc.'s price-to-earnings ratio?
Coherus BioSciences, Inc. (:CHRS) has a price-to-earnings ratio of -279.06 and price/earnings-to-growth ratio is -2.82.
